Industry News

Cerus Corporation announced today announced that, on October 1, 2016, the compensation committee of the company's board of directors granted ten new non-executive employees options to purchase an aggregate of 106,300 shares of the company's common stock with a per share exercise price of $6.26, the closing trading price of the company's common stock on the NASDAQ Global Market on Monday, October 3, 2016. Each option has a ten-year term and will vest over a..."/>
Cerus Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WellCare Health Plans, Inc.,, has developed two incentive programs designed to reward providers for delivering quality care and members for obtaining recommended care. The first program recognizes the vital connection between prenatal care for mothers and positive health outcomes for newborns. In Illinois, one in eight..."/>
Harmony Health Plan Incentive Programs Promote Positive Health Outcomes for Its Members and Their Babies
International Stem Cell Corporation, a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that it has published the results of its preclinical safety studies. The data from a series of in vitro and in vivo preclinical studies show that the company's proprietary ISC-hpNSC ® readily expandable neural stem cells are devoid of undifferentiated pluripotent stem..."/>
International Stem Cell Corporation Publishes Results of Safety Studies Conducted in Support of the First Human Pluripotent Stem Cell Based Therapy for Parkinson’s Disease
Premier’ s holistic population health and cost management solutions. CHARLOTTE, N.C.---- Banner Health, one of the largest nonprofit health systems in the country, has extended and expanded its partnership with Premier Inc., a leading healthcare improvement company. The five-year agreement extends Banner’ s use of Premier’ s group purchasing organization and expands the partnership to integrate supply chain and..."/>
Premier Inc. and Banner Health Expand Partnership
Evolent Health has acquired Valence Health, the company said. The closing merger consideration net of certain closing adjustments is USD219.4 million, and consists of 7.05 million shares of Evolent Class A common stock and USD50.3 million in cash. The transaction also includes additional earn-out potential of up to USD12.4 million, payable in Evolent Class A common stock."/>
Evolent Health purchases Valence Health
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, announced that NARCAN ® Nasal Spray was granted approval by Health Canada.. “This is a life-saving move by Canada’ s health minister who has declared a significant public health emergency,” said Opiant’ s Chief Executive Officer, Roger Crystal, M.D.“ We are pleased that our commercial partner..."/>
Opiant Pharmaceuticals, Inc.’s Partner, Adapt Pharma Limited, Announces NARCAN® Nasal Spray Approved by Health Canada
Organovo Holdings, Inc., a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3 D bioprinting technology, today announced its plan to develop 3 D bioprinted human liver tissue for direct transplantation to patients. The Company is announcing its program to develop this therapeutic tissue based on the achievement of strong results in preclinical studies in animal models showing engraftment,..."/>
Organovo Introduces 3D Bioprinted Human Liver as Leading Therapeutic Tissue in Preclinical Development
Peregrine Pharmaceuticals Inc., PTC Therapeutics Inc., Aratana Therapeutics Inc., and Vanda Pharmaceuticals Inc.. According to a new report by Grand View Research, the global white biotechnology market is expected to grow at a CAGR of 10.2% from 2016 to 2024, while the biofuels segment is forecasted to grow at a CAGR of more than 9% over the same period."/>
Biotech Stocks Technical Reports -- Peregrine Pharma, PTC Therapeutics, Aratana Therapeutics, and Vanda Pharma
Aceto Corporation, the leader in the marketing, sales and distribution of specialty chemicals in the U.S., announced an agreement for sales and distribution of Verdezyne's BIOLON ® DDDA. BIOLON DDDA will be produced by Verdezyne and will be distributed in the United States of America by Aceto. Verdezyne's BIOLON DDDA is produced more..."/>
Verdezyne Signs Distribution Agreement With Aceto Corporation
Catabasis Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, today announced the promotion of Andrew Nichols, Ph.D. to Chief Scientific Officer and Angelika Fretzen, Ph.D., to Senior Vice President of Product Development. Nichols has more than 25 years of drug development experience, leading efforts from target discovery through translational research and early clinical development for pharmaceutical and biotechnology companies."/>
Catabasis Pharmaceuticals Announces Promotion of Andrew Nichols, Ph.D. to Chief Scientific Officer and Angelika Fretzen to Senior Vice President of Product Development
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the appointment of Timothy M. Wright, M.D. as Chief Research and Development Officer reporting to Paul Grint, M.D., President and CEO. Dr. Wright will oversee Regulus' research, drug discovery, clinical development, and regulatory affairs functions. "Tim brings over 30 years of academic and..."/>
Regulus Appoints Timothy M. Wright, M.D. as Chief Research and Development Officer
Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced that its Estonian subsidiary, Teligent OÜ, has received approval from Health Canada's Therapeutic Products Directorate for Lidocaine Ointment USP 5%. This is the sixth approval for Teligent OÜ this calendar year and will be distributed by Teligent's business in Canada. Based on internal estimates, the total addressable market for this product is..."/>
Second Teligent Topical Product Approved by Health Canada
Fate Therapeutics, Inc., a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S."/>
Fate Therapeutics Announces Issuance of U.S. Patent Protecting Enhanced Hematopoietic Stem Cell Compositions
TapImmune Inc., a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer& metastatic disease, today announced its President and Chief Operating Officer, Dr. John Bonfiglio, will be a speaker and deliver a corporate presentation at the BioNetwork Partnering Summit on Wednesday, October 5 at 4:35 PM PT."/>
TapImmune President Dr. John Bonfiglio to Present at BioNetwork Partnering Summit on October 5, 2016
NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release third quarter 2016 financial results after the close of trading on Wednesday, November 2, 2016. Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update.. Individuals interested in listening to the conference call..."/>
NanoString Technologies to Release Third Quarter 2016 Financial Results and Host Conference Call on Wednesday, November 2, 2016
Profound Medical Corp., an emerging medical device company focused on prostate care, announced today that it has received Frost& Sullivan’ s 2016 European Prostate Ablation Systems New Product Innovation Award for its TULSA-PRO TM system.. TULSA-PRO, which received CE Mark approval in April 2016, combines real-time Magnetic Resonance Imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control..."/>
Profound Medical Receives Frost & Sullivan’s 2016 New Product Innovation Award
Immunomedics, Inc., today announced that it has priced an underwritten offering of 10,000,000 shares of common stock and warrants to purchase up to 10,000,000 shares of common stock with anticipated gross proceeds of $30 million. Each share of common stock and accompanying warrant will be priced at $3.00. The warrants will be exercisable six months following the date of issuance, will expire on the second anniversary of the date of issuance and..."/>
Immunomedics Announces $30 Million Financing
Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its single-use version of XCell™ ATF, a proprietary cell retention..."/>
Repligen Launches Single-Use XCell™ ATF System for Bioprocess Intensification
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, today announced that after receiving input from the U.S. Food and Drug Administration, it has determined the next step in the development of MBX-8025 in subjects with primary biliary cholangitis. MBX-8025 is an orally administered potent and selective peroxisome..."/>
CymaBay Therapeutics Announces Plans to Initiate Its Next Phase 2 Study of MBX-8025 in Primary Biliary Cholangitis
DiaMedica Inc. announced that the first patient has been dosed in the Phase Ib clinical trial of DM199, a novel recombinant tissue kallikrein protein for the development of neurological and kidney diseases. "Dosing the first patient in the DM199 study represents another important step toward our goal of providing patients and physicians with treatment options for the currently unaddressed complications of stroke and kidney diseases," said..."/>
DiaMedica Announces First Patient Enrolled in Bridging Clinical Trial for DM199

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary226 Articles
Information Technology215 Articles
Financials174 Articles
Health Care147 Articles
Industrials144 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at